Moya Raquel, Odena M Antonia, Gallego Mayte, de Oliveira Eliandre, Carnés Jerónimo
R&D Allergy & Immunology Unit. LETI Pharma, Madrid, Spain.
Proteomic Platform Core Facility. Parc Científic de Barcelona, Barcelona, Spain.
Clin Exp Allergy. 2022 Feb;52(2):276-285. doi: 10.1111/cea.14067. Epub 2021 Dec 6.
Quantifying major allergens is essential for evaluating the quality and efficacy of allergenic extracts. They are usually measured in non-polymerized extracts using immunoassays. However, the direct measurement of allergens in allergoids is currently not supported. This study set out to develop a method for quantifying Bet v 1 in polymerized birch extracts using mass spectrometry-based targeted analysis.
Three isotopically labelled peptide sequences of Bet v 1 were synthetized and used as internal standards for the development of a mass spectrometry-based targeted analysis. The calibration curves of the three peptides to assess the linearity and limit of detection, as well as reverse calibration curves with a constant amount of sample, were constructed. The Bet v 1 content was determined and measured in 18 batches of depigmented (native extracts purified by a mild acid treatment) and depigmented-polymerized extracts.
Bet v 1 isoforms were identified in both type of extracts by mass spectrometry. According to mass spectrometry-targeted analysis depigmented and depigmented-polymerized extracts exhibited mean values of 70.5 and 73.5 µg Bet v 1/mg of lyophilized extract, respectively. A statistically significant correlation between the allergen content of both extracts was identified. Statistically significant differences were observed when the Bet v 1 content in non-polymerized extracts was measured via mass spectrometry (70.5 ± 11.6 µg/mg) or immunoassay (83.7 ± 19.8 µg/mg).
These results represent the first direct quantification of Bet v 1 in allergoids using mass spectrometry-based targeted analysis. The proposed method demonstrates robustness and reliability and constitutes a promising alternative for detailed characterization of polymerized allergenic extracts.
定量主要过敏原对于评估变应原提取物的质量和疗效至关重要。它们通常使用免疫测定法在非聚合提取物中进行测量。然而,目前尚不支持直接测量变应原疫苗中的过敏原。本研究旨在开发一种基于质谱靶向分析的方法,用于定量聚合桦树提取物中的Bet v 1。
合成了Bet v 1的三个同位素标记肽序列,并用作基于质谱靶向分析方法开发的内标。构建了三条肽的校准曲线以评估线性和检测限,以及具有恒定样品量的反向校准曲线。测定并测量了18批脱色(通过温和酸处理纯化的天然提取物)和脱色聚合提取物中的Bet v 1含量。
通过质谱在两种提取物中均鉴定出Bet v 1亚型。根据质谱靶向分析,脱色和脱色聚合提取物的平均值分别为70.5和73.5 μg Bet v 1/毫克冻干提取物。两种提取物的过敏原含量之间存在统计学上的显著相关性。当通过质谱(70.5±11.6 μg/mg)或免疫测定法(83.7±19.8 μg/mg)测量非聚合提取物中的Bet v 1含量时,观察到统计学上的显著差异。
这些结果代表了首次使用基于质谱的靶向分析对变应原疫苗中的Bet v 1进行直接定量。所提出的方法具有稳健性和可靠性,是详细表征聚合变应原提取物的一种有前景的替代方法。